Joo Ern Ang

Effect of sleep deprivation on the human metabolome

Sarah K. Davies, Joo Ern Ang, Victoria L. Revell et al. · Proceedings of the National Academy of Sciences · 2014 · 538 citations · Full text

Life Sciences, Biochemistry, Metabolic Regulation +14

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With <i>BRCA1</i> or <i>BRCA2</i> Mutations and Recurrent Ovarian Cancer

Stan B. Kaye, Jan Lubiński, Ursula A. Matulonis et al. · Journal of Clinical Oncology · 2011 · 474 citations

Medicine, Oncology, Pharmacology +16

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Debashis Sarker, Joo Ern Ang, Richard D. Baird et al. · Clinical Cancer Research · 2014 · 360 citations · Full text

Medicine, Oncology, Pharmacology +15

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

David Olmos, Hendrik‐Tobias Arkenau, Joo Ern Ang et al. · Annals of Oncology · 2008 · 248 citations · Full text

Medicine, Oncology, Urology +17

Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

Johann S. de Bono, Nicole Concin, David S. Hong et al. · The Lancet Oncology · 2019 · 230 citations · Full text

Medicine, Immunology, Oncology +11